Ticagrelor Tablet
Product Images NDC 53401-028

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 53401-028). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (53401 0028 42)

Label for Ticagrelor 90 mg tablets, containing 1800 tablets per package. The label includes the NDC number 53401-028-42 and states storage instructions between 20-25 degrees Celsius. Manufactured by MSN Pharmaceuticals Inc., Piscataway, NJ, and repackaged by Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN. Marked for prescription use only.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Tica-tabs-fig-01 (Tica Tabs Fig 01)

This is a cumulative incidence curve illustrating the comparison of events over 360 days between patients taking Ticagrelor 90 mg and Clopidogrel. The X-axis represents days from the first study drug dose and the Y-axis shows the cumulative percentage of events. A legend differentiates the solid line for Ticagrelor and the dashed line for Clopidogrel, with patient counts and event percentages noted in the inset.*

FDA Label Image

Tica-tabs-fig-02 (Tica Tabs Fig 02)

A bar chart comparing the percentage of patients who had an event following CABG across different days. The chart shows data for two groups labeled 'T' and 'C' over time intervals from 1 day to 8 or more days, with values plotted as vertical bars for each group per day.*

FDA Label Image

Tica-tabs-fig-03 (Tica Tabs Fig 03)

A line chart showing cumulative percentages over time in months from randomization, comparing two groups labeled Ticagrelor and Placebo. The x-axis represents months ranging from 0 to 54, and the y-axis shows cumulative percentage up to 7%. Two lines depict event rates for each group, with Ticagrelor having a higher cumulative percentage than Placebo throughout the duration. A data table below the x-axis indicates the number at risk for each group at several time points.*

FDA Label Image

Tica-tabs-fig-04 (Tica Tabs Fig 04)

A Kaplan-Meier cumulative incidence graph comparing Ticagrelor 90 mg tablets versus placebo over a 34-day period following randomization. The X-axis represents days, and the Y-axis shows cumulative incidence. The graph plots two curves, one for Ticagrelor and one for placebo, with numbers at risk indicated below the X-axis.*

FDA Label Image

Tica-tabs-fig-05 (Tica Tabs Fig 05)

A pharmacokinetic graph showing platelet reactivity inhibition (PR%) over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and placebo. The y-axis represents PR% inhibition and the x-axis time in hours, illustrating greater and faster inhibition with Ticagrelor compared to Clopidogrel and placebo.*

FDA Label Image

Tica-tabs-fig-06 (Tica Tabs Fig 06)

A dual chart illustrating the percentage of platelet aggregation inhibition (IPA%) induced by 20µM ADP over a 10-day period for Ticagrelor, Clopidogrel, and Placebo, alongside a smaller inset graph showing IPA inhibition at a 24-hour interval across hours post-dose. Ticagrelor shows higher IPA% compared to Clopidogrel and Placebo throughout the timepoints.*

FDA Label Image

Tica-tabs-fig-07 (Tica Tabs Fig 07)

A comparative forest plot chart showing mean effect and 90% confidence intervals of Ticagrelor versus AR-C124910XX across various intrinsic factors such as age, gender, ethnicity, renal impairment, end stage renal disease on hemodialysis, and hepatic impairment. The chart includes pharmacokinetic parameters Cmax and AUC, with recommendations of no dose adjustment for all factors.*

FDA Label Image

Tica-tabs-fig-08 (Tica Tabs Fig 08)

A chart showing the mean effect and 90% confidence interval comparing the drug interactions of Ticagrelor and compound AR-C124910XX with various interacting drugs. The x-axis represents the change relative to a reference, with markers for different drug inhibitors, inducers, and other co-administered drugs. The chart includes recommendations such as avoiding concomitant use or no dose adjustments for specific drug interactions.*

FDA Label Image

Tica-tabs-fig-09 (Tica Tabs Fig 09)

A forest plot chart depicting mean effects and 90% confidence intervals for various interacting drugs taken with Ticagrelor at specified doses. It compares changes in pharmacokinetic parameters (Cmax and AUC) relative to the interacting drug alone, with recommendations for dose adjustments for drugs such as Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine.*

FDA Label Image

Tica-tabs-fig-10 (Tica Tabs Fig 10)

A line chart comparing cumulative event percentages over 360 days from randomization in patients taking 90 mg Ticagrelor and Clopidogrel. The x-axis represents days, and the y-axis shows cumulative event percentages. Ticagrelor's line is solid, Clopidogrel's dashed, with a table summarizing patient numbers, events, hazard ratio, and confidence intervals below the graph.*

FDA Label Image

Tica-tabs-fig-11 (Tica Tabs Fig 11)

A forest plot figure comparing hazard ratios (HR) with 95% confidence intervals for Ticagrelor versus Clopidogrel across various treatment effects, patient subgroups, and demographic characteristics, illustrating relative safety or efficacy outcomes.*

FDA Label Image

Tica-tabs-fig-12 (Tica Tabs Fig 12)

A forest plot chart comparing the hazard ratios (HR) with 95% confidence intervals (CI) for Ticagrelor versus Clopidogrel across different acetylsalicylic acid (ASA) dose groups and regions (US and Non-US). The chart displays subgroup analyses by ASA dose categories (>=300 mg, >100 to <300 mg, <=100 mg) with a vertical axis marking HR values from 0.125 to 8, indicating relative benefits of Ticagrelor or Clopidogrel in those groups.*

FDA Label Image

Tica-tabs-fig-13 (Tica Tabs Fig 13)

A Kaplan-Meier cumulative event curve graph comparing 90 mg and 60 mg doses of Ticagrelor versus placebo over approximately 1200 days from randomization. The graph includes lines for each group, patient numbers at risk over time, and hazard ratios with confidence intervals and p-values, illustrating event probabilities across the study duration.*

FDA Label Image

Tica-tabs-fig-14 (Tica Tabs Fig 14)

A forest plot chart comparing the hazard ratios (HR) and 95% confidence intervals (CI) of ticagrelor versus placebo across multiple patient subgroups characterized by demographics, medical history, and treatment variables. It displays the number of events and event rates per year for both ticagrelor and placebo groups, with a central vertical line at HR=1 and data points indicating the effectiveness direction for ticagrelor or placebo.*

FDA Label Image

Tica-tabs-fig-15 (Tica Tabs Fig 15)

A line graph showing cumulative event percentages over months from randomization comparing Ticagrelor and Placebo. The x-axis represents months from 0 to 54, and the y-axis shows cumulative percentage up to 14%. Two curves are depicted: a solid line for Ticagrelor and a dashed line for Placebo, with event counts and numbers at risk displayed below the graph.*

FDA Label Image

Tica-tabs-fig-16 (Tica Tabs Fig 16)

A forest plot chart depicting hazard ratios (HR) and 95% confidence intervals (CI) comparing Ticagrelor versus placebo across multiple patient subgroups and characteristics. The plot uses square markers to show HR values for each subgroup, with lines representing confidence intervals, illustrating the relative efficacy or risk associated with Ticagrelor compared to placebo.*

FDA Label Image

Tica-tabs-fig-17 (Tica Tabs Fig 17)

A Kaplan-Meier curve graph comparing cumulative percentage events over days from randomization for Ticagrelor 90 mg tablet versus placebo. The graph plots cumulative incidence on the vertical axis and time in days on the horizontal axis, illustrating differences in event rates between the two groups over approximately 34 days.*

FDA Label Image

Tica-tabs-fig-18 (Tica Tabs Fig 18)

A forest plot chart comparing Ticagrelor and placebo across various patient subgroups. It displays hazard ratios (HR) with 95% confidence intervals (CI) for characteristics such as age, sex, race, weight, BMI, geographic region, diagnosis details, and medical history factors. Ticagrelor's effect is shown on the left with values below 1 indicating benefit compared to placebo.*

FDA Label Image

Tica-tabs-structure (Tica Tabs Structure)

Chemical structure of Ticagrelor, illustrating its molecular configuration with labeled atoms and bonds. The diagram shows key functional groups and stereochemistry relevant to this active ingredient in the Ticagrelor 90 mg oral tablet.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.